Cytokine network and T-lymphocytes

The cytokine network and T-lymphocytes represent a complex intercellular signaling system central to the adaptive immune response. T-lymphocytes, or T-cells, rely on a diverse array of cytokines—such as interleukins (IL-2, IL-4, IL-12), interferons (IFN-gamma), and tumor necrosis factors (TNF-alpha)—to govern their maturation, activation, and differentiation into specialized subsets like Th1, Th2, Th17, and regulatory T-cells (StatPearls, NBK554420). This network ensures a coordinated response to pathogens and maintains self-tolerance (NCBI, NBK26890). Dysregulation of this system, characterized by excessive cytokine production or T-cell hyperactivity, is a hallmark of numerous pathologies, including autoimmune disorders (e.g., rheumatoid arthritis, psoriasis), chronic inflammation, and the 'cytokine storm' observed in severe infections (PubMed, 32591409). While not a single therapeutic target, the individual components of this network are frequently targeted by biologics and small molecules to modulate immune activity. For example, TNF inhibitors like adalimumab and IL-6 receptor antagonists like tocilizumab are used to dampen inflammatory responses, while calcineurin inhibitors like cyclosporine directly suppress T-cell activation (Nature Reviews Drug Discovery, 2018). Because this entry describes a broad biological system rather than a discrete molecular entity, it is classified as a network rather than a specific therapeutic target.

Other names

Cytokine-T cell axisT-cell cytokine signaling pathwayCytokine-mediated T-cell activation

Modulation of the immune response through the inhibition of specific cytokines (e.g., TNF-alpha, IL-6, IL-17), blockade of cytokine receptors, or interference with T-cell receptor signaling and costimulatory pathways.